Quantitation of erlotinib in tumours by LC-MS/MS revealed that treatment with PTK787 (an inhibitor of VEGFR tyrosine kinase, PDGFRβ tyrosine kinase, and c-Kit) improved delivery of erlotinib to tumours derived from a lung cancer cell line22, and use of MALDI MSI revealed that inhibition of angiogenesis by bevacizumab improved paclitaxel distribution in tumours derived from an ovarian cancer cell line23. This evidence concerns the gene KIT and neoplasm.